S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
Log in

NASDAQ:RTRX - Retrophin Stock Price, Forecast & News

$13.55
+0.23 (+1.73 %)
(As of 12/10/2019 04:00 PM ET)
Today's Range
$13.27
Now: $13.55
$13.63
50-Day Range
$11.24
MA: $12.73
$14.16
52-Week Range
$10.87
Now: $13.55
$25.53
Volume437,371 shs
Average Volume355,788 shs
Market Capitalization$581.97 million
P/E RatioN/A
Dividend YieldN/A
Beta0.83
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RTRX
CUSIPN/A
Phone760-260-8600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$164.25 million
Book Value$7.72 per share

Profitability

Net Income$-102,680,000.00

Miscellaneous

Employees214
Market Cap$581.97 million
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive RTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter.


Retrophin (NASDAQ:RTRX) Frequently Asked Questions

What is Retrophin's stock symbol?

Retrophin trades on the NASDAQ under the ticker symbol "RTRX."

How were Retrophin's earnings last quarter?

Retrophin Inc (NASDAQ:RTRX) announced its quarterly earnings data on Wednesday, October, 30th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.55. The biopharmaceutical company had revenue of $44.37 million for the quarter, compared to analyst estimates of $45.31 million. Retrophin had a negative net margin of 71.70% and a negative return on equity of 43.88%. The business's quarterly revenue was up 9.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.68) earnings per share. View Retrophin's Earnings History.

When is Retrophin's next earnings date?

Retrophin is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Retrophin.

What price target have analysts set for RTRX?

9 analysts have issued twelve-month target prices for Retrophin's shares. Their forecasts range from $20.00 to $38.00. On average, they expect Retrophin's share price to reach $29.71 in the next twelve months. This suggests a possible upside of 120.1% from the stock's current price. View Analyst Price Targets for Retrophin.

What is the consensus analysts' recommendation for Retrophin?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Retrophin in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Retrophin.

What are Wall Street analysts saying about Retrophin stock?

Here are some recent quotes from research analysts about Retrophin stock:
  • 1. According to Zacks Investment Research, "Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Cholbam, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego. " (11/6/2019)
  • 2. Nomura analysts commented, "in PKU Declined; Frees up ~$65mn. RTRX has declined the option for CNSA-001 after strategic review—this has freed up $65mn in capital (and potential dilution), which may be used for acquisition of new drugs/targets. Recall, RTRX paid $10mn for an option to acquire CNSA-001 program for $65mn in 20% cash/80% stock (at $21.40/sh), plus $25mn in milestone payments, on Jan 4, 2018. New BD a EU PKAN Launch. Stock: FSGS DUPLEX 1H21E (was 2H20E); IgAN 1H22E due to slower- than-expected trial enrollment, steps to speed study completion in progress. Fosmet P3 in PKAN Top Line 3Q19 – Approval Likely Even if Primary Endpoint Misses Stat. Sig. Pending P3 data, RTRX intends to submit both NDA and MAA in 2020. Sensitized primary ep (PKAN-ADL) vs. prior studies (UPDRS) highlights FDA flexibility and breadth of potential to detect clinical benefit. Mgmt." (8/8/2019)

Has Retrophin been receiving favorable news coverage?

News articles about RTRX stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Retrophin earned a news sentiment score of 1.4 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Retrophin.

Who are some of Retrophin's key competitors?

What other stocks do shareholders of Retrophin own?

Who are Retrophin's key executives?

Retrophin's management team includes the folowing people:
  • Ms. Laura M. Clague CPA, CFO & Sr. VP (Age 60)
  • Mr. Neil F. McFarlane, Chief Operating Officer (Age 46)
  • Dr. William E. Rote, Sr. VP and Head of R&D (Age 56)
  • Dr. Noah L. Rosenberg, Chief Medical Officer (Age 52)
  • Dr. Eric M. Dube Ph.D., Pres, CEO & Director (Age 46)

Who are Retrophin's major shareholders?

Retrophin's stock is owned by many different of retail and institutional investors. Top institutional investors include Scopia Capital Management LP (7.50%), State Street Corp (5.01%), Great Point Partners LLC (4.05%), GW&K Investment Management LLC (0.48%), State of New Jersey Common Pension Fund D (0.25%) and Rhumbline Advisers (0.17%). Company insiders that own Retrophin stock include Elizabeth E Reed, Laura Clague, Neil F Mcfarlane, Noah L Rosenberg, Steve Aselage and William E Rote. View Institutional Ownership Trends for Retrophin.

Which major investors are selling Retrophin stock?

RTRX stock was sold by a variety of institutional investors in the last quarter, including Scopia Capital Management LP. Company insiders that have sold Retrophin company stock in the last year include Elizabeth E Reed, Laura Clague, Neil F Mcfarlane, Noah L Rosenberg, Steve Aselage and William E Rote. View Insider Buying and Selling for Retrophin.

Which major investors are buying Retrophin stock?

RTRX stock was bought by a variety of institutional investors in the last quarter, including Great Point Partners LLC, State Street Corp, State of New Jersey Common Pension Fund D, GW&K Investment Management LLC, Massachusetts Financial Services Co. MA, Voloridge Investment Management LLC, Russell Investments Group Ltd. and California Public Employees Retirement System. View Insider Buying and Selling for Retrophin.

How do I buy shares of Retrophin?

Shares of RTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Retrophin's stock price today?

One share of RTRX stock can currently be purchased for approximately $13.50.

How big of a company is Retrophin?

Retrophin has a market capitalization of $579.83 million and generates $164.25 million in revenue each year. The biopharmaceutical company earns $-102,680,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. Retrophin employs 214 workers across the globe.View Additional Information About Retrophin.

What is Retrophin's official website?

The official website for Retrophin is http://www.retrophin.com/.

How can I contact Retrophin?

Retrophin's mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 760-260-8600 or via email at [email protected]


MarketBeat Community Rating for Retrophin (NASDAQ RTRX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  378 (Vote Outperform)
Underperform Votes:  270 (Vote Underperform)
Total Votes:  648
MarketBeat's community ratings are surveys of what our community members think about Retrophin and other stocks. Vote "Outperform" if you believe RTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Featured Article: Fiduciary

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel